Moody Lynn & Lieberson LLC Raises Holdings in Johnson & Johnson $JNJ

Moody Lynn & Lieberson LLC grew its stake in Johnson & Johnson (NYSE:JNJ) by 14.2% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 116,921 shares of the company’s stock after buying an additional 14,511 shares during the quarter. Johnson & Johnson accounts for approximately 1.2% of Moody Lynn & Lieberson LLC’s portfolio, making the stock its 25th biggest position. Moody Lynn & Lieberson LLC’s holdings in Johnson & Johnson were worth $21,679,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of Johnson & Johnson in the 2nd quarter valued at approximately $4,877,174,000. Laurel Wealth Advisors LLC grew its stake in shares of Johnson & Johnson by 15,040.6% during the second quarter. Laurel Wealth Advisors LLC now owns 7,420,699 shares of the company’s stock worth $1,133,512,000 after purchasing an additional 7,371,687 shares in the last quarter. Vanguard Group Inc. increased its holdings in Johnson & Johnson by 1.3% in the second quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock valued at $36,209,060,000 after buying an additional 3,085,180 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in Johnson & Johnson by 159.6% in the second quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock valued at $635,327,000 after buying an additional 2,557,388 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC purchased a new stake in Johnson & Johnson during the 2nd quarter worth about $401,420,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on JNJ shares. Daiwa America raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. Scotiabank began coverage on shares of Johnson & Johnson in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $230.00 price target on the stock. Royal Bank Of Canada set a $240.00 price objective on shares of Johnson & Johnson in a report on Wednesday, December 17th. Guggenheim upped their target price on shares of Johnson & Johnson from $206.00 to $227.00 and gave the company a “buy” rating in a report on Friday, December 5th. Finally, Loop Capital set a $190.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 22nd. Four analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $211.25.

Johnson & Johnson Price Performance

JNJ stock opened at $207.26 on Friday. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $499.35 billion, a P/E ratio of 20.01, a PEG ratio of 2.12 and a beta of 0.34. The business has a 50 day simple moving average of $201.17 and a 200-day simple moving average of $182.64. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $215.18.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.